Table 5.
Unadjusted and adjusted predictors of mortality among patients who were diagnosed with RR-TB between July 2011–June 2012 or between July 2013–July 2014 and who initiated DR-TB treatment in COJ (n = 537)
| n/N | % | HR | 95% CI | Adjusted HR | 95% CI | |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Female | 34/258 | 13.2 | Ref | Ref | Ref | Ref |
| Male | 33/279 | 11.8 | 0.78 | (0.48–1.26) | 0.74 | (0.44–1.22) |
| Age, years | ||||||
| < 30 | 17/138 | 12.3 | Ref | Ref | Ref | Ref |
| 30–45 | 37/283 | 13.1 | 0.92 | (0.52–1.64) | 0.72 | (0.39–1.31) |
| ≥ 45 | 13/119 | 10.9 | 0.75 | (0.36–1.58) | 0.68 | (0.32–1.47) |
| DR-TB classification | ||||||
| RR-TB by Xpert MTB/RIF | 41/237 | 17.3 | 1.16 | (0.58–2.33) | 1.03 | (0.50–2.13) |
| RIF mono-resistant TB | 15/109 | 13.8 | 0.87 | (0.39–1.97) | 0.65 | (0.33–1.81) |
| MDR-TB | 11/191 | 5.8 | Ref | Ref | Ref | Ref |
| HIV status at initiation | ||||||
| HIV negative | 1/61 | 1.6 | 0.14 | (0.02–1.01) | 0.13 | (0.02–0.10) |
| HIV positive on ART | 53/351 | 33.6 | Ref | Ref | Ref | Ref |
| HIV positive not on ART | 10/77 | 12.1 | 1.49 | (0.76–2.94) | 1.49 | (0.75–2.96) |
| HIV status unknown | 3/48 | 6.3 | 0.38 | (0.09–1.54) | 0.36 | (0.09–1.50) |
| Registration year | ||||||
| 2011 | 6/55 | 10.9 | Ref | Ref | Ref | Ref |
| 2012 | 11/108 | 10.2 | 0.89 | (0.33–2.40) | 0.88 | (0.34–2.59) |
| 2013 | 21/166 | 21.7 | 1.3 | (0.55–3.36) | 1.32 | (0.52–3.33) |
| 2014 | 29/211 | 13.7 | 1.45 | (0.59–3.51) | 1.37 | (0.55–3.41) |
| Time to treatment initiation | ||||||
| Without delay | 31/186 | 16.7 | Ref | Ref | Ref | Ref |
| Delayed (deferred) | 35/332 | 10.5 | 0.89 | (0.54–1.45) | 0.91 | (0.53–1.56) |
HR Hazard Ratio, CI Confidence interval, RR-TB Rifampicin resistant TB, MTB Mycobacterium tuberculosis, MDR-TB Multi-drug resistant tuberculosis, XDR-TB Extensively drug-resistant tuberculosis; ART antiretroviral therapy, RIF rifampicin, DR-TB drug resistant TB p < 0.05 bold